Ladirubicin
Ladirubicin (PNU-159548) is a derivative of Daunorubicin. Ladirubicin exhibits DNA intercalation and DNA alkylating properties, inhibits DNA replication and transcription, causes DNA damage, and thereby exhibits antitumor efficacy. Ladirubicin exhibits the potential to penetrate the blood-brain barrier (BBB) for its high lipophilicity. Ladirubicin exhibits toxicity through suppression of bone marrow activity[1].
Product Specifications
CAS Number
171047-47-5
Product Name Alternative
PNU-159548
UNSPSC
12352005
Target
DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ladirubicin.html
Smiles
C[C@H]1[C@@H](OS(C)(=O)=O)[C@@H](N2CC2)C[C@](O1)([H])O[C@@H]3C4=C(O)C(C(C5=CC=CC=C5C6=O)=O)=C6C(O)=C4C[C@](C(C)=O)(O)C3
Molecular Formula
C29H31NO11S
Molecular Weight
601.62
References & Citations
[1]Monneret C. Recent developments in the field of antitumour anthracyclines. Eur J Med Chem. 2001 Jun;36 (6) :483-93.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Gm1661 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)
SNORA54 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
Munc18-1 Recombinant Antibody, AbBy Fluor™ 594 Conjugated
Munc18-1 Recombinant Antibody, AbBy Fluor™ 594 Conjugated